FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide. The company today announced that it is presenting and participating via the on-demand session at the H.C. Wainwright 24th Annual Global Investment Conference taking place Sept. 12-14, 2022. Beginning Monday, Sept. 12, interested parties may access FSD Pharma’s on-demand presentation by visiting https://ibn.fm/mPBst, where it will be hosted for 90 days. In addition, the presentation and supporting materials will be available shortly thereafter on the FSD Pharma website within the “For Investors” section. “We are extremely motivated to develop and commercialize FSD Pharma’s portfolio of novel therapeutics and working with high quality institutional investors is instrumental in meeting our goals,” said Dr. Lakshmi Kotra, who serves as CEO of FSD Pharma’s wholly owned subsidiary Lucid Psycheceuticals. Dr. Kotra also provides development oversight for the complete FSD Pharma pipeline. “As one of the country’s premier annual conferences, we look forward to the H.C. Wainwright event to interact with the investment community and elucidate on the tremendous potential of our pipeline.”
To view the full press release, visit https://ibn.fm/g5QCA
About FSD Pharma Inc.
FSD Pharma is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences Inc., a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases. Lucid Psycheceuticals Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-Psych and Lucid-MS. Lucid-Psych is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. For more information, visit the company’s website at www.FSDPharma.com.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
